Clinical Trials Logo

Filter by:
NCT ID: NCT04520425 Terminated - Clinical trials for Chronic Migraine, Headache

Osteopathic Manipulative Techniques for the Treatment of Chronic Migraine Headaches

SMART-CM
Start date: September 8, 2022
Phase: N/A
Study type: Interventional

This study evaluates a standardized osteopathic manipulative therapy (OMT) as a treatment for chronic migraine headaches. It will determine the feasibility of enrolling patients in standardized osteopathic manipulative therapy trials, the acceptability of this specific treatment to patients, and evaluate its preliminary effectiveness.

NCT ID: NCT04517864 Terminated - Alopecia Areata Clinical Trials

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

Allegro2a
Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).

NCT ID: NCT04515693 Terminated - Acute Stroke Clinical Trials

Exploring Psychometric Properties of a New Version of the 6MWT in the Acute Stroke Population

Start date: March 25, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to assess inter- and intra-rater reliability of the 6MWT in people with acute stroke who require various levels of assistance with walking.

NCT ID: NCT04515394 Terminated - Clinical trials for Colorectal Neoplasms

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Start date: January 28, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC) having acquired resistance to anti-epidermal growth factor receptor (EGFR) antibody targeted therapy due to mesenchymal epithelial transition (MET) amplification.

NCT ID: NCT04511819 Terminated - COVID-19 Clinical Trials

Losmapimod Safety and Efficacy in COVID-19

LOSVID
Start date: August 28, 2020
Phase: Phase 3
Study type: Interventional

The therapeutic hypothesis for the use of losmapimod in COVID-19 disease is that increased mortality and severe disease is caused by p38 mitogen-activated protein kinase (MAPK)-mediated exaggerated acute inflammatory response resulting from SARS-CoV-2 infection. The study Sponsor hypothesizes that the early initiation of p38α/β inhibitor therapy in patients hospitalized with moderate COVID-19 who are at increased risk of a poor prognosis based on older age and elevated systemic inflammation will reduce clinical deterioration including progression to respiratory failure and death. To address this hypothesis, Fulcrum Therapeutics is conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of losmapimod versus placebo in subjects 40 and older who are hospitalized with moderate COVID-19 disease.

NCT ID: NCT04511650 Terminated - COVID-19 Clinical Trials

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

RESCUE
Start date: October 21, 2020
Phase: Phase 2
Study type: Interventional

This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID) (every 8 hours [Q8H]), in hospitalized subjects with moderate to severe Coronavirus disease 2019 (COVID-19) receiving standard of care therapy. The study was planned to include 2 parts with Part 1 comprising the dose escalation period of the study and Part 2 comprising the proof-of-concept safety and efficacy period of the study.

NCT ID: NCT04511026 Terminated - Endometrial Cancer Clinical Trials

Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer

Start date: January 20, 2021
Phase: Phase 2
Study type: Interventional

The goal of this study is to (i) improve detection of sentinel nodes and (ii) reduce additional surgical dissection that is needed in case a sentinel lymph node cannot be detected.

NCT ID: NCT04510285 Terminated - Gastric Cancer Clinical Trials

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Start date: August 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether treatment with trastuzumab combined with pembrolizumab will improve the clearance of tumor DNA from participants' bodies after surgery.

NCT ID: NCT04509739 Terminated - Infant Development Clinical Trials

Effect of Music Intervention on Infants' Brainstem Encoding of Speech

Start date: October 16, 2019
Phase: N/A
Study type: Interventional

Infants' frequency-following response (FFR) to a nonnative lexical tone, reflecting early sensory encoding of speech in the auditory system will be evaluated pre- and post- music intervention at 7 mo and 11 mo of age. The lab-controlled music intervention starts at 9 mo of age and consists of 12 sessions of social and multimodel musical activities with the aim to synchronize infants' movements with musical beats.

NCT ID: NCT04508764 Terminated - Lynch Syndrome Clinical Trials

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

Start date: April 9, 2021
Phase: N/A
Study type: Interventional

The purpose of this research study is to learn how cancer care providers can help their patients communicate the need for genetic testing in families with inherited cancer syndromes.